A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Adult Subjects With Moderate-to-Severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy
Latest Information Update: 21 Sep 2026
At a glance
- Drugs Cenerimod (Primary)
- Indications Systemic lupus erythematosus
- Focus Registrational; Therapeutic Use
- Acronyms OPUS-1
- Sponsors Idorsia Pharmaceuticals
Most Recent Events
- 15 Sep 2026 Planned End Date changed from 1 May 2027 to 30 Sep 2027.
- 15 Sep 2026 Planned primary completion date changed from 31 Oct 2026 to 31 Mar 2027.
- 30 Apr 2026 Status changed from recruiting to active, no longer recruiting.